Peptide Market Expands
FDA Panel Backs BPC-157, Sending Hims & Hers Stock Soaring on Peptide Market Hopes
Anonymous
Key Points
1
The FDA advisory committee vote was 8 to 6 with one abstention, signaling a narrowly divided panel and that final policy may hinge on further FDA review.
2
Market outlook for peptide therapies in telehealth is strong, with analysts projecting the peptide-enabled telehealth market to reach about $2.2 billion by 2027.
3
Hims & Hers has been positioning for peptide therapy expansion by acquiring a manufacturing facility last year to increase production capacity.
4
Following the vote, Hims & Hers stock jumped roughly 11% intraday and traded around the mid-teens to mid-$30s per share (around $34.78 per share in reported coverage).
5
The near-term technical picture shows the stock trading below its 20-day moving average but above the 50-day and 200-day moving averages, indicating some near-term selling pressure within a longer-term bullish trend.
An FDA advisory panel voted 8 to 6 on July 23, 2026, to add BPC-157 to the 503A Bulks List — a regulatory move that would let compounding pharmacies use the peptide in customized treatments. Shares of Hims & Hers Health jumped roughly 11% intraday on the news, according to Investing.com.
The decision puts Hims & Hers in a strong position to enter the growing peptide therapy market. Analysts project that market could reach $2.2 billion by 2027. The company already has over 2 million subscribers and a market cap of about $8.1 billion, per GuruFocus.
FDA Panel's Close Vote Opens Peptide Market Door
The FDA advisory committee's vote was narrow — 8 in favor, 6 against, with one abstention. That slim margin means the final decision is not guaranteed. The FDA panel's recommendation is advisory only. The agency still needs to make a formal ruling before compounding pharmacies can legally use BPC-157, according to GuruFocus.
BPC-157 is a peptide, meaning a small chain of amino acids. Compounding pharmacies mix custom drug formulations for patients. Adding BPC-157 to the 503A Bulks List gives those pharmacies a legal path to include it in treatments. That is a major regulatory unlock for telehealth companies like Hims & Hers, according to TS2 Space.
Hims & Hers Already Built to Handle Peptide Demand
Hims & Hers did not wait for the FDA vote to start preparing. The company acquired a manufacturing facility last year to boost production capacity for peptide therapies. That move now looks well timed. It gives the company a head start on rivals if the FDA finalizes the BPC-157 ruling.
The company offers telehealth services across hair loss, sexual health, and mental wellness. Adding peptide therapies would open a new revenue stream. Analysts at TS2 Space noted the vote shifts market attention toward revenue per subscriber — a key metric for Hims & Hers' long-term growth story.
Stock Jumps But Insiders Have Been Selling
Hims & Hers shares rose about 6.4% to $33.72 in some reports, while other outlets tracked an intraday jump closer to 11%, with the stock touching around $34.78 per share, according to Yahoo Finance and Investing.com. The surge reflects investor excitement about the peptide market opportunity.
But there are caution signals too. Insiders sold about $3.9 million in shares over the past three months. The stock also trades below its 20-day moving average, a sign of short-term selling pressure. It does sit above its 50-day and 200-day moving averages, which points to a longer-term bullish trend, per GuruFocus.
What Comes Next for Hims and Peptide Therapy Access
The FDA's formal ruling will be the real turning point. If the agency follows the panel's advice, compounding pharmacies across the U.S. could start offering BPC-157 treatments. That would give telehealth platforms a legal, scalable way to sell peptide therapies directly to patients online.
The peptide-enabled telehealth market is projected to hit $2.2 billion by 2027. Hims & Hers, with its existing subscriber base and new manufacturing capacity, is positioned to capture a large share. The panel vote was close, but the direction is clear — peptide therapies are moving toward mainstream access, according to Yahoo Finance.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
15
Articles
30
Reach
45
A
AnonymousAuthor